A Phase 1 Clinical Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Effects of a Single Dose of VSA001 Injection in Chinese Healthy Adult Volunteers
Latest Information Update: 24 Mar 2025
At a glance
- Drugs VSA 001 (Primary)
- Indications Cardiovascular disorders; Metabolic disorders
- Focus Adverse reactions
- Sponsors Visirna Therapeutics
- 20 Mar 2025 Status changed from not yet recruiting to completed.
- 15 Mar 2023 New trial record